People discussed using peppermint, lavender, rosemary, and pumpkin seed oils for hair regrowth or thickening. They shared personal experiences and recommendations on using these oils alone or in combination.
A person transitioning is using 2mg sublingual estradiol and 2.5mg oral minoxidil daily for hair regrowth, noting significant progress in three months. They plan to increase estrogen dosage and consider adding dutasteride, discussing the effects and challenges of transitioning.
Pyrilutamide did not show effectiveness in regrowing hair compared to a placebo, but it may still help maintain existing hair by preventing DHT from causing follicle miniaturization. Some users believe it could be beneficial when used with other treatments like minoxidil, finasteride, and dutasteride.
A user shared a six-month update on hair improvement using Pyrilutamide and Minoxidil, noting significant hair regrowth and strength. Some participants questioned the legitimacy of the results and the source of Pyrilutamide.
A new alcohol-free, propylene glycol-free topical finasteride foam is available for prescription in Canada and the USA, offering a cleaner alternative for hair loss treatment. The product also offers a combination of 0.1% finasteride with 5% minoxidil and aims to be affordable and less irritating for sensitive scalps.
The conversation discusses concerns about the efficacy of pyrilutamide if left in a mailbox for several hours. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.
A user shared their experience using RU58841, Minoxidil, and Finasteride for hair loss, noting good results but increased acne from RU58841. They plan to replace RU58841 with Finasteride while continuing Minoxidil.
A participant using Veradermics VDPHL01, an extended-release oral minoxidil, experienced significant hair regrowth from Norwood 6 to Norwood 3V without side effects. They plan to use dutasteride after the treatment to maintain results.
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
A user is attempting to recover from severe hair loss using 1.25mg finasteride, 5mg topical minoxidil twice daily, pyrilutamide for a month, RU58841 for two weeks, and weekly microneedling at 1.5mm. They have seen new hair growth after two months and plan to continue the treatment for a year with the hope of regrowing enough hair for a transplant.
A case study that suggests verteporfin may be able to help regrow donor hairs after FUE extraction, and the potential implications of this result. Treatments discussed include Minoxidil, Finasteride, and RU58841.
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.
The conversation is about choosing a topical antiandrogen for hair loss, with options including RU58841, CB0301, Pyrolutamide, Alfatradiol, and Fluridil. Users discuss their preferences and reasons for selecting specific treatments.
PP405 is expected to finish Phase 2 trials in late 2025, with potential market availability around 2028-2029 if all goes well. Current treatments like finasteride and minoxidil are still popular, while new options like KX-826 and Breezula are anticipated soon.
The user has been using dutasteride, RU58841, and minoxidil for hair loss, experiencing some side effects and mixed results, with RU58841 notably reducing scalp itch. Despite extensive treatment, the user has maintained hair but struggles with hairline thickening.
Kintor's KX826 (pyrilutamide) is ineffective at 0.5% and overpriced at 1%, leading to user frustration and calls for fair pricing. Users suggest sticking with proven treatments like Minoxidil and Finasteride.
The user is treating diffuse thinning with finasteride, dutasteride, and oral minoxidil but hasn't seen significant improvement. Others suggest that results vary, with some maintaining hair and others considering transplants or future treatments.
A user started taking 0.25mg of finasteride every other day to prevent hair loss and documented their experience. Initially, they felt anxious and had headaches, but by the second week, they felt normal with no side effects or changes in hair.
User discusses hair regrowth using RU58841, minoxidil, and dutasteride. Many users praise the progress and ask about the treatments' effectiveness and side effects.
The user is experiencing ongoing hair loss despite using a comprehensive treatment regimen including dutasteride, oral minoxidil, cyproterone acetate, transdermal estradiol, and topical bicalutamide. They suspect cyproterone acetate may be worsening their hair loss and are considering switching to injection monotherapy.
The conversation discusses hair loss treatments, specifically the use of anti-androgens like RU58841 and Pyrilutamide, which are expensive in India. Alternatives like spironolactone and concerns about the effectiveness of finasteride and dutasteride are also mentioned.
The conversation discusses a prescription for hair loss treatment. Minoxidil is mentioned as a treatment that should be used daily, not just two days a week.
Bryan Johnson uses Dutasteride, Latanoprost, Minoxidil with Tretinoin, and other unproven treatments, while Derek uses Finasteride, Minoxidil, Nizoral, RU58841, and Castor Oil. Kevin uses Finasteride, Minoxidil, RU58841, and Alfatradiol, but is against Nizoral and microneedling, preferring Tretinoin for absorption.
Combining 0.5 mg oral finasteride with topical finasteride and minoxidil during an Enclomiphene cycle may help manage increased DHT levels. Monitoring for side effects is advised.
The conversation discusses the use of Verteporfin in hair loss treatment. It suggests that Verteporfin could potentially regenerate hair follicles instead of forming scars, providing an unlimited donor supply for hair transplants.
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.